European Committee on Antimicrobial Susceptibility Testing-Recommended Rapid Antimicrobial Susceptibility Testing of Escherichia coli, Klebsiella pneumoniae, and Staphylococcus aureus From Positive Blood Culture Bottles
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background: Early diagnosis and treatment are important for a good prognosis of bloodstream infections. The European Committee on Antimicrobial Susceptibility Testing (EUCAST) recommends rapid antimicrobial susceptibility testing (RAST) based on the disk diffusion methodology for 4, 6, and 8 hours of incubation. We evaluated EUCAST-RAST of Escherichia coli, Klebsiella pneumoniae, and Staphylococcus aureus from positive blood culture bottles. Methods: Twenty strains of E. coli, K. pneumoniae, and S. aureus were tested using EUCAST-RAST. Ten antimicrobial agents against E. coli and K. pneumoniae and four agents against S. aureus were tested. The diameter of the inhibition zone (mm) was compared with the minimal inhibitory concentration (μg/mL) obtained using the Sensititre AST system (TREK Diagnostic Systems, East Grinstead, UK). Results: For E. coli, the percentage of total categorical agreement (CA) was 69.5% at 4 hours, and 87% at 8 hours. For K. pneumoniae, the total CA was 89% at 4 hours, and 95.5% at 6 hours. For S. aureus, the total CA was 100% after 4 hours. Discrepancies were observed mainly for E. coli with β-lactam antimicrobial agents, and the numbers of errors decreased over time. Conclusions: EUCAST-RAST for K. pneumoniae and S. aureus met the United States Food and Drug Administration criteria at 6 and 4 hours, respectively, whereas that for E. coli did not meet the criteria for up to 8 hours. RAST can shorten the turn-around testing time by more than one day; therefore, if applied accurately according to laboratory conditions, antimicrobial agent results can be reported faster.
Abstract
Background: Early diagnosis and treatment are important for a good prognosis of bloodstream infections. The European Committee on Antimicrobial Susceptibility Testing (EUCAST) recommends rapid antimicrobial susceptibility testing (RAST) based on the disk diffusion methodology for 4, 6, and 8 hours of incubation. We evaluated EUCAST-RAST of Escherichia coli, Klebsiella pneumoniae, and Staphylococcus aureus from positive blood culture bottles. Methods: Twenty strains of E. coli, K. pneumoniae, and S. aureus were tested using EUCAST-RAST. Ten antimicrobial agents against E. coli and K. pneumoniae and four agents against S. aureus were tested. The diameter of the inhibition zone (mm) was compared with the minimal inhibitory concentration (μg/mL) obtained using the Sensititre AST system (TREK Diagnostic Systems, East Grinstead, UK). Results: For E. coli, the percentage of total categorical agreement (CA) was 69.5% at 4 hours, and 87% at 8 hours. For K. pneumoniae, the total CA was 89% at 4 hours, and 95.5% at 6 hours. For S. aureus, the total CA was 100% after 4 hours. Discrepancies were observed mainly for E. coli with β-lactam antimicrobial agents, and the numbers of errors decreased over time. Conclusions: EUCAST-RAST for K. pneumoniae and S. aureus met the United States Food and Drug Administration criteria at 6 and 4 hours, respectively, whereas that for E. coli did not meet the criteria for up to 8 hours. RAST can shorten the turn-around testing time by more than one day; therefore, if applied accurately according to laboratory conditions, antimicrobial agent results can be reported faster.
참고문헌 (28)
- Goto M, "Overall burden of bloodstream infection and nosocomial bloodstream infection in North America and Europe", Clin Microbiol Infect, 19, pp.501~509 (2013)
- Martinez RM, "Bloodstream infections", Microbiol Spectr, 4, pp.653~689 (2016)
- Seymour CW, "Assessment of clinical criteria for sepsis : for the Third International Consensus Definitions for Sepsis and Septic Shock(Sepsis-3)", JAMA, 315, pp.762~774 (2016)
- Cecconi M, "Sepsis and septic shock", Lancet, 392, pp.75~87 (2018)
- Ferrer R, "Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study", Am J Respir Crit Care Med, 180, pp.861~866 (2009)
- Ferrer R, "Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour : results from a guideline-based performance improvement program", Crit Care Med, 42, pp.1749~1755 (2014)
- Puskarich MA, "Association between timing of antibiotic administration and mortality from septic shock in patients treated with a quantitative resuscitation protocol", Crit Care Med, 39, pp.2066~2071 (2011)
- Vilella AL, "Timing and appropriateness of initial antibiotic therapy in newly presenting septic patients", Am J Emerg Med, 32, pp.7~13 (2014)
- Sterling SA, "The impact of timing of antibiotics on outcomes in severe sepsis and septic shock : a systematic review and meta-analysis", Crit Care Med, 43, pp.1907~1915 (2015)
- Munita JM, "Mechanisms of antibiotic resistance", Microbiol Spectr, 4, pp.481~511 (2016)
- Grundmann H, "Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study", Lancet Infect Dis, 17, pp.153~163 (2017)
- Denis B, "Prevalence, risk factors, and impact on clinical outcome of extended-spectrum beta-lactamase-producing Escherichia coli bacteraemia: a five-year study", Int J Infect Dis, 39, pp.1~6 (2015)
- Nordmann P, "Global spread of carbapenemase-producing Enterobacteriaceae", Emerg Infect Dis, 17, pp.1791~1798 (2011)
- Wilson ML, "Manual of clinical microbiology", pp.15~28 (2015)
- Yu So Hyun, "Ten-Year Prevalence Trends of Phenotypically Identified Community-Associated Methicillin-Resistant Staphylococcus aureus Strains in Clinical Specimens", Annals of Laboratory Medicine, 41(4), pp.386~393 (2021), 대한진단검사의학회[DOI]
- Turnidge JD, "Manual of clinical microbiology", pp.1246~1252 (2015), Wiley
- Jorgensen JH, "Manual of clinical microbiology", pp.1253~1273 (2015), Wiley
- Karlowsky JA, "Manual of clinical microbiology", pp.1274~1285 (2015), Wiley
- Bauer A, "Antibiotic susceptibility testing by a standardized single disc method", Am J Clin Pathol, 45, pp.149~158 (1966)
- CLSI, "Performance standards for antimicrobial susceptibility testing. 32nd ed. CLSI M100", Clinical and Laboratory Standards Institute, ~ (2022)
- European Committee on Antimicrobial Susceptibility Testing, "Breakpoint tables for interpretation of MICs and zone diameters. version 12.0", European Committee on Antimicrobial Susceptibility Testing, ~ (2022)
- Kahlmeter G, "Point-counterpoint : differences between the European committee on antimicrobial susceptibility testing and Clinical and Laboratory Standards Institute recommendations for reporting antimicrobial susceptibility results", J Clin Microbiol, 57, pp.e01129-19~ (2019)
- European Committee on Antimicrobial Susceptibility Testing, "Methodology-EUCAST rapid antimicrobial susceptibility testing (RAST) directly from positive blood culture bottles version 3.0", European Committee on Antimicrobial Susceptibility Testing, ~ (2022)
- European Committee on Antimicrobial Susceptibility Testing, "Zone diameter breakpoint tables for rapid antimicrobial susceptibility testing (RAST) directly from blood culture bottles version 5.1", European Committee on Antimicrobial Susceptibility Testing, ~ (2022)
- Kim D, "Major bloodstream infection-causing bacterial pathogens and their antimicrobial resistance in South Korea, 2017-2019: phase I report from Kor-GLASS", Front Microbiol, 12, pp.799084~ (2022)
- CLSI, "Performance standards for antimicrobial susceptibility testing. 29th ed. CLSI M100", Clinical and Laboratory Standards Institute, ~ (2019)
- European Committee on Antimicrobial Susceptibility Testing, "Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST version 12.0", European Committee on Antimicrobial Susceptibility Testing, ~ (2022)
- U.S. Food and Drug Administration, "Class II special controls guidance document: antimicrobial susceptibility test (AST) systems", Food and Drug Administration, ~ (2009)